MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
Provided By PR Newswire
Last update: Mar 20, 2025
Top-Line Data From MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in April of 2025
Announced Positive Top-Line 16-Week Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH, in December, Demonstrating Direct Hepatic Action in Addition to Its Glucose Lowering Effect
Read more at prnewswire.comNASDAQ:MTVA (6/18/2025, 8:10:20 PM)
0.7
+0.01 (+1.16%)
Find more stocks in the Stock Screener
